Nausicaa Malissen
Centre National de la Recherche Scientifique · 118 works · 1,986 citations · h-index 17
Top works
- Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
- Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
- Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
- Macrophage activation syndrome: A new complication of checkpoint inhibitors
- The scalp hair collar and tuft signs: A retrospective multicenter study of 78 patients with a systematic review of the literature
- Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions
- Diabetes and Blood Glucose Disorders Under Anti-PD1
- Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients
- Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery
- Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study
- Symmetrical Intertriginous and Flexural Exanthema due to Bortezomib (a Proteasome Inhibitor) Given for Myeloma
- Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives
- Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer
- Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
- Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy
- HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma
- Cross-cultural adaptation into French and validation of the SCAR-Q questionnaire
- A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule
- Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma
- Plasmocytomes cutanés primitifs multiples